Loading...
Loading...
BioLife Solutions, Inc.
BLFS today announced that CardioCell, a Stemedica Cell Technologies company, recently published details of its phase II heart failure clinical trial in the Journal of Cardiovascular Medicine. In the article, titled, Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy, the use of BioLife's clinical grade CryoStor freeze media was disclosed. Details of the study can be found here:
A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
Over the last several years, adoption of BioLife's biopreservation media products including CryoStor and HypoThermosol in the developing and high growth regenerative medicine market has increased significantly due to the products' ability to extend stability and improve viability and functional recovery of starting material and manufactured cell products.
Mike Rice, BioLife's President & CEO, remarked, "We are very proud to support CardioCell and Stemedica in their quest
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in